.jpg "Scott C. Cribbes photo")
Market Development Leader
Revvity, United Kingdom
I hold a Biochemistry Honours Degree from Glasgow University and a PhD in Cancer biology from Beatson Institute for Cancer Research.
The next 5 years were spent honing my research and assay development techniques at British Biotech, Axis Shield and AstraZeneca before joining the dark side aka the commercial world in 2001 where I worked in various customer focused roles at Applied Biosystems and Life Technologies, mainly in the area of imaging and HTS screening and reagents solutions. I have had the pleasure of working with the Celigo image cytometer technology. This encompassed its birth and growth from a brightfield only instrument at Cyntellect to its 5 channel format at Nexcelom and its continual development within the Revvity family. From 2018 to 2022 I headed up the Nexcelom business in EMEAI delivering double digit growth year on year. 2023 saw a new challenge with the complete integration of Nexcelom into Perkin Elmer and the transformation of our new company into Revvity. My current role is the Market Development Leader for the Cellular imaging portfolio, which contains the legacy Nexcelom cell counting and imaging systems as well as legacy Perkin Elmer high content systems.
Revvity is a life science and diagnostic provider that combines the expertise of many legacy companies such as BioLegend, Cisbio, Horizon, Nexcelom, Oxford Immunotech, Perkin Elmer plate readers, high content systems animal IVIS imaging systems and Sirion biotech. This allows us to really provide a fit for purpose solutions to many of our customers workflow needs